CMC Pharma Consulting BJ ApS: Financial statements 2022
CVR: 41988592
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
CMC Pharma Consulting BJ ApS (CVR 41988592) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 5,176,271 and a net result of DKK 345,175 compared with DKK 611,221 the year before. That is an increase of 46.9% compared with the year before. Equity in the 2022 report amounted to DKK 396,396. The solvency ratio was 49.6%. The company had 1 employee in the financial year.
- Gross Profit
- DKK 5,176,271
- Profit/Loss
- DKK 345,175
- Equity
- DKK 396,396
- Total Assets
- DKK 798,710
- Employees
- 1
Official annual report
Keep an eye on CMC Pharma Consulting BJ ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
CMC Pharma Consulting BJ ApS has published its annual report for 2021. Gross profit came to DKK 3,524,020, and the net result was DKK 611,221.
About CMC Pharma Consulting BJ ApS
CMC Pharma Consulting BJ ApS is a Danish company of the type Anpartsselskab based in Rungsted Kyst, founded in 2021. The company is registered under the industry Anden teknisk rådgivning. The management consists of Babak Jamali. The company is owned by Babak Jamali. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK 1,764,114 and a net result of DKK 30,653 compared with DKK 127,570 the year before. Equity in the 2025 report amounted to DKK 111,190.